Survey and Reduction of Mortality in Peridialysis Uremic Patients Via Intervention of Risk Factors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

2500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-01

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In patients with non-dialysis-dependent end stage kidney disease (ESKD) the common transition of care to renal replacement therapy is dialysis. Each year over 70 000 Chinese transition from non-dialysis-dependent ESKD to dialysis. Whereas dialysis therapy is intended to be life-sustaining, ESKD patients have a 10-fold or higher risk of death compared with the general population. Mortality rates are even higher upon transition and in the first year, especially in the first 3 to 6 months following the transition to dialysis, yet it remains unknown which is the contributing cause of this high death rate. Hence, there is an urgent need to examine the emerging field of Transition of Care in ESKD. We suggest the term "peridialysis period" for this transition period for ESKD patients, so that the transition of care from non-dialysis-dependent ESKD to dialysis ESKD can be more pragmatically defined and studied. In the current study, we will investigate the mortality and its risk factors of ESKD patients during peridialysis period, and improve the survival rate and quality of life of peridialysis ESKD patients by intervening the risk factors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Benefit of Hemodialysis Plus Hemoperfusion on Mortality

NCT03227770

End-stage Renal Disease

COMPLETED NA

Urgent-start Peritoneal Dialysis in ESRD Patients：A Multi-center Study

NCT02946528

End-Stage Renal Disease

COMPLETED NA

Effect of Different Dialysis Dosage on Prognosis in Maintenance Peritoneal Dialysis Patients

NCT00912821

End-stage Renal Disease

COMPLETED PHASE4

A Clinical Study on the Impact of Hemoperfusion on the Prognosis of Uremic Patients Undergoing Maintenance Hemodialysis

NCT06981559

Hemodialysis

NOT_YET_RECRUITING

High-flux Hemodialysis Versus Hemodiafiltration for End-Stage Renal Disease

NCT03456232

Chronic Kidney Failure

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

End Stage Renal Disease on Dialysis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

intervention group

Through the effective intervention of risk factors for death in patients with dialysis, the effect of mortality of peri-dialysis patients was observed.

Group Type EXPERIMENTAL

intervention group

Intervention Type COMBINATION_PRODUCT

Through effective intervention combined with drugs and dietary guidance within 3 to 6 months, all the observation markers including blood pressure and laboratory results will reach the target target value.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

intervention group

Through effective intervention combined with drugs and dietary guidance within 3 to 6 months, all the observation markers including blood pressure and laboratory results will reach the target target value.

Intervention Type COMBINATION_PRODUCT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who have been diagnosed with end stage kidney disease (eGFR\<15ml/min/1.73m2) or newly started dialysis with 3 months at all hospitals in Yangzhou, China since January 1, 2016

Exclusion Criteria

* Patients who have had a history of dialysis and have been transferred to Yangzhou during this period;
* patients who are transferred to a dialysis area outside Yangzhou City
* Patients who give up dialysis treatment
* patient whose renal function recover and stop dialysis treatment;
* Patient who receive kidney transplantation

Eligible Sex

ALL

Accepts Healthy Volunteers

No